ProCE Banner Activity

New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Slideset

In these downloadable slides, leading experts discuss the current therapeutic landscape for advanced EGFR-mutated NSCLC, unmet needs in the progressive disease setting, and the promise of novel investigational agents targeting HER3.

Released: December 17, 2024

Expiration: December 16, 2025

Share

Faculty

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.